{"resourceType": "Group", "meta": {"versionId": "9", "lastUpdated": "2024-10-22T15:49:43.988Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/cohort-definition"]}, "title": "CohortDefinition: T2DM-specific criteria", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "CohortDefinition: T2DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279346. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279346. Computable resource at: https://fevir.net/resources/Group/279346."}}], "url": "https://fevir.net/resources/Group/279346", "id": "279346", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "279346", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "membership": "conceptual", "combinationMethod": "all-of", "characteristic": [{"description": "Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria", "code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "method": [{"text": "based on the World Health Organization (WHO) diagnostic criteria"}], "valueCodeableConcept": {"coding": [{"system": "http://snomed.info/sct", "code": "44054006", "display": "Diabetes mellitus type 2 (disorder)"}]}, "exclude": false}, {"description": "Have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine", "code": {"text": "Medication exposure"}, "valueCodeableConcept": {"text": "Daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs)\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"}, "exclude": false, "durationDuration": {"comparator": ">=", "value": 1, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}}, {"description": "Are between 20 and 70 years old at the time of informed consent", "code": {"coding": [{"system": "http://snomed.info/sct", "code": "397669002", "display": "Age"}]}, "valueRange": {"low": {"value": 20, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}, "high": {"value": 70, "unit": "years", "system": "http://unitsofmeasure.org", "code": "a"}}, "exclude": false, "timing": [{"contextCode": {"coding": [{"system": "http://snomed.info/sct", "code": "182771004", "display": "Informed consent for procedure"}]}, "offsetDuration": {"value": 0}}]}, {"description": "Have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "code": {"coding": [{"system": "http://loinc.org", "code": "39156-5", "display": "Body mass index (BMI) [Ratio]"}]}, "valueRange": {"low": {"value": 18.5, "unit": "kilogram per square meter (kg/m2)", "system": "http://unitsofmeasure.org", "code": "kg/m2"}, "high": {"value": 35, "unit": "kilogram per square meter (kg/m2)", "system": "http://unitsofmeasure.org", "code": "kg/m2"}}, "exclude": false, "timing": [{"contextCode": {"text": "screening"}, "offsetDuration": {"value": 0}}]}], "description": "i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>"}}